FASTBASE

“Decision with Precision”

The Intellectual Property

There is an increasing pipeline of targeted cancer therapies. However, there is limited precision in linking patients with therapy. The consequence of this limitation is a cost burden to society, a missed opportunity and a quality of life burden to patients.

FASTBASE SOLUTIONS has developed a high specificity, super-sensitive, quantitative biomarker platform employing A-FRET. This platform is designed to report on protein activation states and protein complex formation in situ, e.g. tumour biopsies.

FASTBASE SOLUTIONS investigates cell-cell interaction through determining cell-surface receptor and ligand synergy. Determining cell-cell contact provides insight into host communication with alternative cells including cancer cells. A specific example is an interaction between a patient’s immune system and tumour cells, providing a greater insight into host-tumour communication and the mechanisms involved in immune-mediated tumour destruction, immune-suppression and therapy resistance. FASTBASE SOLUTIONS, therefore, provides a platform for immune-therapy dosing regimen design.

#

Our Assets

FASTBASE SOLUTIONS offer a precision patient treatment through the use of more thorough and specific cancer prognosis.

FASTBASE SOLUTIONS have developed a high specificity, super-sensitive, quantitative biomarker platform employing A-FRET. This platform is designed to report on protein activation states and protein complex formation in situ e.g. tumour biopsies.

This quantitative imaging platform is an amplified signal imaging set-up for diagnostics and prognosis of cancer, enabling the evaluation of clinical efficiency of personalised cancer treatments.

It is an imaging system, composed of a proprietary adapted microscope powered by software based on a proprietary time-resolved A-FRET technique.